<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03502668</url>
  </required_header>
  <id_info>
    <org_study_id>ASTX727-03</org_study_id>
    <nct_id>NCT03502668</nct_id>
  </id_info>
  <brief_title>Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS</brief_title>
  <official_title>A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astex Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety,
      pharmacodynamics, pharmacokinetics, and hematologic response in subjects with IPSS risk
      category of low-risk or Intermediate-1 MDS. This study will be conducted in two phases. In
      phase 1 subjects will be randomized into 3 cohorts in a 28-day cycles. Phase 2, 80 new
      subjects will be randomized in a 1:1 ratio into 2 doses/schedules.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1-2, multicenter, open-label study of various ASTX727 LD doses and schedules to
      assess the safety, pharmacodynamics (PD), pharmacokinetics (PK), and hematologic response in
      subjects with IPSS risk category of low-risk or Intermediate-1 MDS. The study will be
      conducted in 2 phases.

      Phase 1: In Stage A, subjects will be randomized into 3 cohorts of 6 subjects each testing
      different doses of oral decitabine with cedazuridine in 28-day cycles. When safety has been
      established in Phase 1 Stage A, Phase 1 Stage B will open, wherein additional 30 subjects
      will be randomized in a 1:1:1 ratio into 3 cohorts of 10 subjects.

      Phase 2: Using 2 doses/schedules one of which will be selected from Phase 1, 40 additional
      subjects per dose/schedule will be randomized in a 1:1 ratio. The selected doses/schedules
      will be evaluated for safety (drug-related AEs), efficacy (including hematologic response),
      PD (LINE-1 methylation, and fetal hemoglobin as fraction of total hemoglobin), and PK.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Multicenter, open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of drug-related Grade ≥3 Adverse Events (AEs) or dose-limiting toxicities (DLTs) (if any) for each cohort dose/schedule</measure>
    <time_frame>18-24 months</time_frame>
    <description>Phase 1: Safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematologic response based on normalization of conversion of any baseline cytopenia or anemia (hemoglobin response, neutrophil response, platelet response, transfusion independence)</measure>
    <time_frame>18-24 months</time_frame>
    <description>Phase 2: Efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>%LINE-1 methylation change from baseline</measure>
    <time_frame>18-24 months</time_frame>
    <description>pharmacodynamics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>18-24 months</time_frame>
    <description>pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>18-24 months</time_frame>
    <description>pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration (Tmax)</measure>
    <time_frame>18-24 months</time_frame>
    <description>pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (t1/2)</measure>
    <time_frame>18-24 months</time_frame>
    <description>pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic response (Phase 1 only) based on normalization of conversion of any baseline cytopenia or anemia (hemoglobin response, neutrophil response, platelet response, transfusion independence)</measure>
    <time_frame>18-24 months</time_frame>
    <description>Phase 1: Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to bone marrow blasts &gt;5%</measure>
    <time_frame>18-24 months</time_frame>
    <description>Number of days from the date of randomization to the date when bone marrow blasts are &gt;5% and increased by ≥50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival</measure>
    <time_frame>18-24 months</time_frame>
    <description>Number of days from the date of randomization to the date when bone marrow or peripheral blood blasts reach ≥20%, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>18-24 months</time_frame>
    <description>Number of days from the date of randomization to the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Phase 1 Stage A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 cohorts of 6 subjects each in a schedule in 28-day cycles of ASTX727 LD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Stage B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 cohorts of 10 subjects each in 28-day cycles of ASTX727 LD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 additional subjects randomized in a 1:1 ratio studying two different doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASTX727 LD</intervention_name>
    <description>oral decitabine (LD) + cedazuridine (E7727)</description>
    <arm_group_label>Phase 1 Stage A</arm_group_label>
    <arm_group_label>Phase 1 Stage B</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
    <other_name>oral decitabine (LD) + cedazuridine (E7727)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASTX727 SD</intervention_name>
    <description>oral decitabine (SD) + cedazuridine (E7727)</description>
    <arm_group_label>Phase 2</arm_group_label>
    <other_name>oral decitabine (SD) + cedazuridine (E7727)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to understand and comply with the study procedures, understand the risks involved
             in the study, and provide written informed consent before the first study-specific
             procedure.

          2. Men or women ≥18 years with IPSS low risk or Int-1 MDS (all subjects). Subjects must
             have had at least 1 of the following disease-related criteria during the 8 weeks
             before randomization:

               1. Red blood cell (RBC) transfusion dependence of 2 or more units of RBCs or Hb of
                  &lt;8.5 g/dL in at least 2 blood counts prior to randomization.

               2. ANC of &lt;0.5 × 10^9/L in at least 2 blood counts prior to randomization.

               3. Platelet counts of &lt;50 × 10^9/L in at least 2 blood counts prior to
                  randomization.

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

          4. Adequate organ function.

          5. Women of child-bearing potential (according to recommendations of the Clinical Trial
             Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a
             negative pregnancy test at screening.

          6. Women of child-bearing potential must agree to use contraceptive measures of birth
             control for 6 months after completing treatment; men must use contraceptive measures
             and agree not to father a child for at least 3 months after completing treatment.

        Exclusion Criteria:

          1. Treatment with any investigational drug or therapy within 2 weeks before study
             treatment.

          2. Treatments for MDS must be concluded 1 month prior to study treatment.

          3. Diagnosis of chronic myelomonocytic leukemia (CMML).

          4. Poor medical risk because of other conditions such as uncontrolled systemic diseases
             or active uncontrolled infections.

          5. Prior malignancy, except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, prostate cancer or breast cancer under control with
             hormone therapy, or other cancer from which the subject has been disease free for at
             least 1 year.

          6. Known active infection with human immunodeficiency virus or hepatitis viruses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuri Sano, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Astex Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuri Sano, MD, PhD</last_name>
    <phone>925-560-2844</phone>
    <email>yuri.sano@astx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harold N Keer, MD, PhD</last_name>
    <phone>925-719-0741</phone>
    <email>harold.keer@astx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nandika S Nagodawithana, MBBS, MSc, MD, MSHI</last_name>
      <phone>205-934-6624</phone>
      <email>nandika@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Kimo Bachiashvili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Schatz, BS, CCRP</last_name>
      <phone>720-848-0628</phone>
      <email>derek.schatz@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Pollyea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BRCR Medical Center Inc.</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Losada</last_name>
      <phone>561-447-0614</phone>
      <phone_ext>106</phone_ext>
      <email>alosada@brcrglobal.com</email>
    </contact>
    <investigator>
      <last_name>Harshad Amin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Prada, MD</last_name>
      <phone>813-745-2071</phone>
      <email>william.cisnerosprada@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>David A Sallman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Hospital - Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Weisenbach, RN</last_name>
      <phone>317-278-0597</phone>
      <email>jweisenb@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Larry Cripe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Clinical Research Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Firth-Braun, RN, BSN</last_name>
      <email>jfirthbraun@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Abdulraheem Yacoub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders (RCCA MD LLC - Maryland Division)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Bongiorno, RN, MSHS</last_name>
      <phone>301-571-2016</phone>
      <email>nbongiorno@regionalcancercare.org</email>
    </contact>
    <investigator>
      <last_name>Victor Priego, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amberley Proctor, RN, BSN</last_name>
      <phone>402-836-9171</phone>
      <email>amberley.proctor@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Lori Maness, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krista Belko, PhD</last_name>
      <phone>716-845-3373</phone>
      <email>krista.belko@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Griffiths, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nurse</last_name>
      <phone>844-482-4812</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>William Donnellan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Ft. Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindi Schoenfeldt, RN</last_name>
      <phone>817-413-1645</phone>
      <email>cindi.schoenfeldt@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Richey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Frazer, RN, BSN</last_name>
      <phone>713-745-5468</phone>
      <email>jafraser@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Guillermo Garcia-Manero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Ponce, RN</last_name>
      <phone>210-595-5692</phone>
      <email>Debbie.Ponce@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Roger Lyons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Poe</last_name>
      <phone>903-579-9800</phone>
      <email>karen.poe@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Habte Yimer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen McClain, RN, BSN, OCN</last_name>
      <phone>757-213-5658</phone>
      <email>karen.mcclain@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Paul Conkling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>December 1, 2019</last_update_submitted>
  <last_update_submitted_qc>December 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>low risk myelodysplastic syndromes, MDS, ASTX727</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

